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The optimal antithrombotic therapy after coronary 
stenting in patients with atrial fibrillation (AF) remains a 
clinical conundrum (1). Most patients with AF require life-
long oral anticoagulation to reduce the risk of ischemic 
stroke and/or extracranial thromboembolism (2). Direct 
oral anticoagulants (DOACs) constitute today the best 
therapeutic option for preventing cardio-embolic events 
while reducing the risk of intracranial hemorrhage 
compared with vitamin K antagonists (VKAs) (2). Patients 
with acute coronary syndrome (ACS) or undergoing 
percutaneous coronary intervention (PCI) are all candidates 
to dual antiplatelet therapy consisting of aspirin and P2Y12 
inhibitors to prevent the recurrence of platelet-mediated 
coronary events, especially those related to the stent (3,4). 
This therapeutic strategy prevents stent thrombosis by a 
greater extent (over 5-folds risk reduction) than aspirin 
alone or aspirin combined with oral anticoagulants (5,6). 
As many as 20% to 40% of patients with AF undergo PCI 
and, from the reverse perspective, 5% to 10% of patients 
candidate to PCI present with AF (1). The coexistence of 
the two conditions complicates the therapeutic approach 
because combining an oral anticoagulant with dual 
antiplatelet therapy into the so-called triple antithrombotic 
therapy  increases  the  r i sk  o f  f a ta l  and  nonfa ta l 
bleeding (7). As a potential alternative, a modified—
double—antithrombotic regimen, combining oral 
anticoagulation with a single antiplatelet agent (usually 
a P2Y12 inhibitor), has been proposed to reduce the 
risk of bleeding while preventing ischemic events. In 
the contemporary setting of DOACs, four randomized-
controlled trials investigated a triple versus double therapy in 
patients with AF receiving PCI: the PIONEER AF-PCI (8), 
the RE-DUAL PCI (9), the AUGUSTUS (10), and the 
ENTRUST AF-PCI (11).
In the AUGUSTUS trial (10), Lopes and colleagues 
randomly ass igned—with a  two-by-two factor ia l 
design—4,614 patients with AF after ACS or following 
PCI to receive (I) apixaban 5 mg bid or VKAs (open-label 
comparison), and (II) aspirin or matching placebo (blinded 
comparison). Patients were followed up for 6 months to 
evaluate for a primary (safety) endpoint of major or clinically 
relevant non-major bleeding according to the International 
Society on Thrombosis and Hemostasis criteria, and 
secondary (efficacy) endpoints including the composite 
of death, hospitalization or death, and ischemic events 
[myocardial infarction (MI), stroke, urgent revascularization, 
or stent thrombosis]. According to the design of the study, 
double antithrombotic regimen consisted of apixaban plus 
a P2Y12 inhibitor (93% clopidogrel, 6% ticagrelor, and 
1% prasugrel) reached through an early drop of aspirin. At 
6 months, the primary endpoint was significantly reduced 
by apixaban compared with VKAs [hazard ratio (HR) 0.69; 
95% confidence interval (CI): 0.58–0.81; P<0.001], and 
increased by aspirin compared with placebo (HR 1.89; 95% 
CI: 1.59–2.24; P<0.001). Moreover, apixaban associated 
with a lower risk of death or hospitalization than VKAs (HR 
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0.83; 95% CI: 0.74–0.93; P=0.002), while no difference was 
noted by comparing aspirin versus placebo.
By means of its design and inclusion/exclusion criteria, 
the AUGUSTUS trial adds numerous insights into 
the findings of the other DOAC-based trials (10). By 
randomizing patients in a two-by-two factorial fashion, 
the trial specifically addressed the individual impact of 
DOACs and aspirin withdrawal, demonstrating that both 
aspects worth in terms of bleeding prevention. Contrarily, 
the PIONEER AF-PCI, RE-DUAL PCI, and ENTRUST 
AF-PCI trials only partly answered this clinical question as, 
according to the design of the studies, it was not possible to 
determine whether the safety benefit of a double strategy 
was due to the use of a DOAC-based strategy or early 
aspirin discontinuation. Besides, the AUGUSTUS also 
included a proportion of patients with medically managed 
ACS (about one-quarter of study participants), who are 
known to be at high risk for future events, expanding 
current knowledge in this particular setting. However, 
findings from the AUGUSTUS did not provide evidence 
that early omission of aspirin is safe in all patients, nor 
clearly indicated the optimal timing for the transition from 
triple to double therapy. First, an initial period of triple 
antithrombotic therapy before randomization was granted 
to all patients in all the trials, for a maximum of 14 days 
in the AUGUSTUS, 5 days in the RE-DUAL PCI and 
ENTRUST AF-PCI, and 3 days in the PIONEER AF-PCI. 
Thus, the effect of a very early (or peri-procedural) aspirin 
discontinuation remains actually unexplored and should 
not be pursued. Moreover, in the AUGUSTUS, while a 
reduction in the risk of bleeding was shown in patients on 
placebo compared with those on aspirin, a signal for an 
absolute increase in the risk of MI, definite/probable stent 
thrombosis, and urgent revascularization, and was detected. 
For stent thrombosis, this rate was almost doubled when 
aspirin was early discontinued (HR 0.58, 95% CI: 0.28–
1.22), with the majority of events (80%) occurring within 
30 days of PCI (12). Whether the extensive use of 
clopidogrel and its variable response and efficacy 
(particularly without aspirin) played a relevant role in this 
setting remains uncertain. The consistency of the trends 
toward more coronary events in the placebo than in the 
aspirin group strongly supports the biological plausibility 
of the finding and suggests that a significant difference 
would likely be detected if more patients had been enrolled. 
Indeed, the AUGUSTUS (as the other trials) was largely 
underpowered to reliably detect differences in this respect 
considering that, in contemporary practice, cardiac and 
cerebrovascular ischemic events are roughly ten-fold less 
prevalent than bleeding occurrences (adopted as the primary 
endpoint in all these studies).
To tackle this relevant open-issue, a recent meta-
analysis pooled aggregate data from the four DOAC-based 
trials (13). In a total population of 10,234 patients, double 
antithrombotic therapy, consisting of a DOAC and a P2Y12 
inhibitor, significantly reduced bleeding events, including 
major and intracranial hemorrhages, while it increased the 
risk of MI and stent thrombosis with a statistical borderline 
and significant effect, respectively. These findings carry 
relevant clinical implications. First, given the totality and 
consistency of results, DAOCs should be prioritized in 
all patients with AF who have an ACS or receive PCI, as 
a superior safety over VKAs appears to be a class effect. 
Second, the increase in ischemic cardiac events with double 
therapy highlights (once again) the importance of a precise 
and fully individualized approach in deciding the duration 
of the initial course of triple therapy in these patients (14). 
Individual risk factors of bleeding and ischemic events 
continuously interact with each therapeutic intervention 
and should be comprehensively taken into account in the 
selection of the optimal antithrombotic regimen (14,15). 
The exercise to carefully assess clinical, laboratory, and 
procedural factors that are known to influence major 
bleeding and myocardial infarction remains essential to 
predict the net benefit/harm for each individual patient and 
guide decision-making (Figure 1). In patients deemed at low 
risk of cardiac ischemic events (i.e., those receiving elective 
PCI, without high-risk clinical or angiographic features) 
or at high risk of major bleeding, early discontinuation 
of aspirin and treatment with a DAOC combined with 
clopidogrel is warranted (3). Conversely, in patients 
presenting with ACS, high thrombotic burden, undergoing 
complex, high-risk, or multivessel PCI, continuing aspirin 
should be advised for at least several weeks or longer, and 
triple therapy duration tailored to patient’s bleeding risk (3) 
(Figure 1). Although treatment simplification is attractive, 
dropping aspirin very early is unlikely to benefit all patients. 
The still enduring belief that a one-size-fits-all approach 
is the way forward should also probably be “dropped” in 
practice and trials.
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